ASTRAZENECA PHARMA INDIA LTD. - 506820 - Clarification sought from AstraZeneca Pharma India Ltd
The Exchange has sought clarification from AstraZeneca Pharma India Ltd on July 06, 2022, with reference to Movement in Volume.The reply is awaited.
Canada to throw out 13.6 million doses of AstraZeneca Covid vaccine
Canada is going to throw out about 13.6 million doses of the Oxford-AstraZeneca COVID-19 vaccine because it couldn't find any takers for it either at home or abroad ASTRAZENECA PHARMA INDIA LTD. - 506820 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to the Regulation 30 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, we hereby inform that an interaction with analyst / investor is scheduled to be held as per the attachment.
Mid-cap debt-free pharma stock finalizes record date for 400% dividend
In the pharmaceutical industry, AstraZeneca Pharma India Ltd. is a mid-cap company with a market cap of Rs. 6,822 crore. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Record Date For Payment Of Final Dividend
Further to our intimation dated May 26, 2022, we wish to inform that the Record Date for determining the entitlement of the shareholders for the payment of the Final Dividend for financial year 2021-22 is July 8, 2022. The Final Dividend, if approved by the shareholders, shall be paid/dispatched to the shareholders on or before September 6, 2022. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Closure of Trading Window
This is to inform you that, in accordance with the provisions of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, the Trading Window for dealing in the Shares of the Company remains closed from June 16, 2022 and the same shall reopen after 48 hours from the declaration of Unaudited Financial Results of the Company for the quarter ending June 30, 2022. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Disclosure Of Related Party Transactions
Pursuant to the provisions of Regulation 23 (9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, we enclose herewith the disclosure of Related Party Transactions for half year ended March 31, 2022 for your information and records. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing a copy of newspaper advertisement published in Business Standard and Prajavani newspapers. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Board Meeting Outcome for Recommendation Of Final Dividend For The Financial Year 2021-22
We would wish to inform that at the Meeting of the Board of Directors of the Company held on May 26, 2022, the Board have recommended a Final Dividend of Rs. 8/- per equity share of Rs. 2/- each, subject to the approval of shareholders at the forthcoming Annual General Meeting of the Company. The dividend, if approved, by the shareholders, will be credited/dispatched within 30 days from the date of Annual General Meeting of the Company.
